Search PubMed⌕ Search

PubMed · 1858309

Exaggerated warfarin sensitivity: a case report.

Abstract

A 64-y-old male was hospitalized because of significant bleeding and a prolonged prothrombin time (PT) (greater than 200 sec) following an inadvertent doubling of his anticoagulant dose. He was previously well controlled on 2.5 mg warfarin every fourth day. Treatment included vitamin K, fresh frozen plasma, and packed red blood cells. Warfarin plasma concentrations, clotting factor analysis (CFA) and PTs were analyzed to evaluate this patient. Following hospitalization, the patient was followed by the Anticoagulation Clinic and his dose was stabilized at 0.5 mg daily. He experienced no further bleeding episodes and his PT ratio was maintained at 1.5 times control. The response to a dose of warfarin varies greatly from patient to patient. Previous reports of abnormal responses to warfarin can be categorized as either warfarin "resistant" or "sensitive." The preponderance of reports are compliance or hereditary warfarin resistance. This patient represents a case of exaggerated warfarin sensitivity that cannot be easily explained. There was no evidence of a drug interaction, warfarin concentrations were not excessive, and CFA was reflective of a moderate warfarin effect. Extreme tissue sensitivity to warfarin is a plausible explanation for this abnormal response.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G J Vanscoy, J W McAuley. 1991. Exaggerated warfarin sensitivity: a case report.. https://pubmed.ncbi.nlm.nih.gov/1858309/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Prophylactic treatment of a small child with severe factor VII deficiency using repeat dosing from a single vial of recombinant activated factor VII.

We report our experience with a small child with severe factor VII deficiency and a history of frequent and spontaneous life-threatening hemorrhage. The patient has received several years of successful prophylactic treatment with an every 3-day infusion program in which she receives recombinant activated factor VII (rVIIa) using multiple doses from a single reconstituted vial over a 72-hr period. Comparison is made to prophylactic treatment in this same patient using plasma-derived factor VII (PDVII) using a prothrombin complex concentrate (PCC).

Blood Coagulation Factors↗

Heparin-induced inhibitory effects of a prothrombin complex concentrate on global tests of haemostasis.

Prothrombin complex concentrates (PCC) have been used as bypassing agents for the treatment of haemophilia A patients with inhibitor as well as for replacement therapy in congenital and acquired deficiencies of vitamin-K-dependent clotting factors. The efficacy of PCC is variable, however, especially during long-term and high-dose use, and all currently available products of this nature contain heparin. We have examined the haemostatic properties of PCC using reconstituted whole blood made by mixing coagulation-factor-deficient plasma and washed blood cells. In rotation thromboelastometry (ROTEM), the recommended therapeutic dose of Proplex ST corrected the abnormal patterns. At higher concentrations, however, the ROTEM patterns regressed. In addition, specific assays of coagulation factors appeared unreliable in the presence of 2.5 U/ml Proplex ST; the abnormalities were corrected when protamine sulfate was added. The findings suggest that the presence of heparin in PCC might have a greater effect on global haemostasis. Careful attention to the anticoagulant effect as well as thrombogenicity of PCC is required. Monitoring therapy using such as ROTEM analysis could be highly informative.

Blood Coagulation Factors↗